Cargando…

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

AIM: Selexipag is an oral selective prostacyclin receptor agonist approved for treatment of patients with pulmonary arterial hypertension (PAH). In the present study, we aim to assess the safety and efficacy of selexipag in triple combination therapy with endothelial receptor antagonists (ERAs) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Xiaopei, Lu, Weida, Zhang, Deyuan, Qie, Liangyi, Li, Haijun, Li, Xiao, Liu, Hui, Ji, Qiushang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530145/ https://www.ncbi.nlm.nih.gov/pubmed/36204579 http://dx.doi.org/10.3389/fcvm.2022.991586

Ejemplares similares

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Case report: Rescue treatment with add-on selexipag in a preterm infant with suprasystemic pulmonary hypertension, pulmonary capillary hemangiomatosis, and isolated pulmonary vein stenosis
por: Hasan, Hosan, et al.
Publicado: (2022)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Echocardiographic Prognosis Relevance of Attenuated Right Heart Remodeling in Idiopathic Pulmonary Arterial Hypertension
por: Zhao, Qin-Hua, et al.
Publicado: (2021)

Correlation between serum GDF-15 level and pulmonary vascular morphological changes and prognosis in patients with pulmonary arterial hypertension
por: Maimaiti, Yasenjiang, et al.
Publicado: (2023)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Differences in disease severity and prognosis of exercise-induced right-to-left shunt between idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients
por: Wang, Shang, et al.
Publicado: (2022)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Novel hub genes associated with pulmonary artery remodeling in pulmonary hypertension
por: Tan, Rubin, et al.
Publicado: (2022)

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension
por: Krause, A, et al.
Publicado: (2017)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Association between right atrial area measured by echocardiography and prognosis among pulmonary arterial hypertension: a systematic review and meta-analysis
por: Liu, Ke, et al.
Publicado: (2020)

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension
por: Zhang, Yi, et al.
Publicado: (2021)

Notopterol Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat
por: Huang, Lin, et al.
Publicado: (2022)

An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers
por: Santos-Gomes, Joana, et al.
Publicado: (2022)

Management of pregnant patients with pulmonary arterial hypertension
por: Zhang, Xiao, et al.
Publicado: (2022)

Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
por: Lai, Jinzhi, et al.
Publicado: (2022)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Circulating Interleukin-7 in Human Pulmonary Arterial Hypertension
por: Diekmann, Franziska, et al.
Publicado: (2021)

Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report
por: Rossi, Serena, et al.
Publicado: (2020)

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy
por: Adachi, Shiro, et al.
Publicado: (2022)

Pregnant outcomes of critically ill pregnant patients with pulmonary hypertension: A multicenter retrospective study
por: Zhang, Lin, et al.
Publicado: (2022)

Construction of a diagnostic signature and immune landscape of pulmonary arterial hypertension
por: Duo, Mengjie, et al.
Publicado: (2022)

Case report: Thoughts on two cases of total anomalous pulmonary venous connection complicated with pulmonary artery hypertension
por: Yan, Ling, et al.
Publicado: (2023)

Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
por: Gong, Su-Gang, et al.
Publicado: (2021)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Donepezil Ameliorates Pulmonary Arterial Hypertension by Inhibiting M2-Macrophage Activation
por: Qiu, Haihua, et al.
Publicado: (2021)

Autoimmunity in Pulmonary Arterial Hypertension: Evidence for Local Immunoglobulin Production
por: Shu, Ting, et al.
Publicado: (2021)

Prognostic Value of Gamma-Glutamyltransferase in Male Patients With Idiopathic Pulmonary Arterial Hypertension
por: Lu, Gang-Hua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rkjujkobregbhdehh9ju1gj4jf